Upside | ||||||
|---|---|---|---|---|---|---|
| VRNA | 5.61% | aa.aa | 84.340 | -1.40% | 58,904 | |
| ALKS | 4.06% | aa.aa | 31.71 | +2.29% | 113,203 | |
| AXSM | 4.00% | aa.aa | 111.91 | +1.13% | 31,657 | |
| RNA | 3.50% | aa.aa | 36.24 | +1.83% | 85,552 | |
| AKRO | 3.48% | aa.aa | 54.28 | +0.63% | 56,780 | |
| RYTM | 3.48% | aa.aa | 68.11 | +2.92% | 45,222 | |
| PTCT | 3.30% | aa.aa | 52.13 | +0.77% | 56,067 | |
| ZLAB | 3.21% | aa.aa | 38.11 | +4.30% | 74,601 | |
| MRUS | 3.17% | aa.aa | 56.21 | +0.36% | 49,884 | |
| ACAD | 2.90% | aa.aa | 21.98 | +3.00% | 116,710 |
ALPS ETF Trust - ALPS Medical Breakthroughs ETF is an exchange traded fund launched and managed by ALPS Advisors, Inc. The fund invests in the public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences, biotechnology sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the S-Network Medical Breakthroughs Index, by using full replication technique. ALPS ETF Trust - ALPS Medical Breakthroughs ETF was formed on December 29, 2014 and is domiciled in the United States.